Lachlan MacKinnon (L) and Adrian Woolfson (Replay)

With AAV al­ter­na­tive and DNA writ­ing tech, a new hub-and-spoke start­up wants to ‘de­moc­ra­tize’ gene ther­a­pies

When Adri­an Woolf­son was head of R&D at Sang­amo, he be­gan con­tem­plat­ing start­ing his own com­pa­ny. His goal? Solve some of the key chal­lenges plagu­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.